Trichostatin A (TSA)

目录号:S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。

该物品暂时缺货。请留下您的电子邮件地址,有存货的时候我们将通过邮件通知您。

您只要点击‘到货通知’ 并留下您的电子邮件地址您将得到10%的折扣。

到货通知

客户使用该产品的6个实验数据:

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系,包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖,平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系,抑制HDAC活性,平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同,Trichostatin A 抑制这些HDACs,且抑制程度相似, IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞,通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体,而诱导转化生长因子βⅡ型受体(TβRII) 表达,复合体与TβRII 启动子的DNA片段结合,伴随着Sp1乙酰化,且与复合体相关的HDAC数理全部降低。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MVfGeY5kfGmxbjDBd5NigQ>? NF7nXIExNjgQvF2= M4HnblI1cA>? NWPvWndR\XSqYX7vcC=> NFLPUJhmdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn M3H3dFI2Pzh5MEe5
TE13 M1PLdWZ2dmO2aX;uJGF{e2G7 MVqwMlPPxE1? MmL5NlRp MVX1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= M3T2ZVI2PTd7Nk[1
TE13 M4nIXmFxd3C2b4Ppd{BCe3OjeR?= M2XRfVAvO87:TR?= NE\5fXQzPGh? MWHpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v M{HIfVI2PTd7Nk[1
MEFs MVfGeY5kfGmxbjDBd5NigQ>? MVi1{txO MkjINVZp NYjkW2kxcW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w M4iyR|I2PDh{NkO0
SW480  MkTrSpVv[3Srb36gRZN{[Xl? NXL6bGw2OC5zzszN NIfsdYo1QGh? NVH0dJRjTE2VTx?= NXPuOnlJemW4ZYLz[ZMhTU2W NYPx[pZKOjV2M{S5PVc>
PC3  MVrGeY5kfGmxbjDBd5NigQ>? NED1OHQxNjIQvF2= MnHZOFhp NHjFOY5FVVOR NVjQSmIyemW4ZYLz[ZMhTU2W MV6yOVQ{PDl7Nx?=
SW480  MVHGeY5kfGmxbjDBd5NigQ>? NXHrNWVPOC5zzszN NXLFTXhuPDiq M3;Hc2ROW09? NF3CW5hifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NV;abGNEOjV2M{S5PVc>
PC3  NWizU3E5TnWwY4Tpc44hSXO|YYm= M1vMXVAvOc7:TR?= MmTmOFhp NWTEZ2JTTE2VTx?= MX3heJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? MUiyOVQ{PDl7Nx?=
SW480  M3XJTmZ2dmO2aX;uJGF{e2G7 M4fMWFAvOc7:TR?= M{TIN|Q5cA>? NHLuRW5FVVOR M1LtN4lv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MmPQNlU1OzR7OUe=
PC3  NX\wb2hxTnWwY4Tpc44hSXO|YYm= NYXjVJMxOC5zzszN NGHWUoQ1QGh? NFfST4VFVVOR NVzuTlNEcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NX63PVRGOjV2M{S5PVc>
A431 NFrWdWZCeG:ydH;zbZMhSXO|YYm= MkLYNk8yOC93MD:xNFBvVQ>? MUO0PIg> NXzF[G1tTE2VTx?= MW\pcohq[mm2czD0bIUh[2WubDDndo94fGh? NGPBd24zPTN5MUC2PS=>
A431 M2LsO2Z2dmO2aX;uJGF{e2G7 NHS2eXk2OG6P NV;BfY9FOi94L{GyM|I1cA>? MmjuSG1UVw>? NUi4cXFn[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NI\1foozPTN5MUC2PS=>
MDA-MB-231 NVzvUnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSwMVYxOG6P Mn;4NlRp NHiycJVFVVOR NYjnR|hMUUN3MDDv[kAyODCwTR?= M3nKcVI2OTl{N{Kx
MCF7 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHkbooxNTZyMH7N NWm3XGZKOjSq MlGxSG1UVw>? MnnkTWM2OCCxZjC3OY5O NEXnfZUzPTF7MkeyNS=>
SKOV-3 NFj3SGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHDW|gyNTFyzszN NFniRpMzPGh? MUHEUXNQ NWXVW4NJUUN3MDDv[kA2NjcQvF2= NYTQeXdXOjVzNkm0PVE>
A549 NEDvSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjwVWEyNTFyzszN M1zKdVI1cA>? MW\EUXNQ MWjJR|UxKG:oIEOuNu69VQ>? MVWyOVE3QTR7MR?=
SKOV-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PwSlAvOS1zzszN M1vDOlQ5cA>? NHLKOXRFVVOR M{PDTmlEPTBib3[gNE44|ryP NVPXNnlPOjVzNkm0PVE>
A549 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37GT|AvOS1zzszN M3vBUlQ5cA>? NX72cnRtTE2VTx?= MWXJR|UxKG:oIECuNljPxE1? NVzrVItzOjVzNkm0PVE>
SKOV-3 NFPkUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnKWpgxNjBzLUCuPe69VQ>? M4ftRlczcA>? Ml\nSG1UVw>? NVPQO2hJUUN3MDDv[kAxNjN{zszN M1W3eFI2OTZ7NEmx
A549 NXLEeJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvhNE4xOS1yLkpOwG0> M{S3UVczcA>? NVzJO5VoTE2VTx?= MnPNTWM2OCCxZjCwMlA3|ryP MkXoNlUyPjl2OUG=
HeLa M1zNZ2Z2dmO2aX;uJGF{e2G7 NWnqNphiOjVybl2= MXyxOog> MU\EUXNQ M2X4bIlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= M4HXR|I2OTF4Nki4
CNE2 NELpTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHCZ2EzOTByLU[wNI5O MlriNlQwPDhxN{Lo NXTKcVI1cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NVXjRpdVOjR7Nkm5NFE>
PC3 NIjqOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvNVAxNTFyMEDuUS=> MYCyOIg> MULJR|UxKG:oIEOwNI5O M{jKbFI1QDV2NkW4
LNCaP MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVexNFAuOTByMH7N NVP5Z|BMOjSq MYLJR|UxKG:oIEOwNI5O M{Hl[lI1QDV2NkW4
HeLa  M{m4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:1VZM5Os7:TR?= MVW0PIg> MmfD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= NX35[3R6OjR6NE[xN|U>
HMEC-1  M3;LWWZ2dmO2aX;uJGF{e2G7 M2fLflMxOG6P MXeyOIg> M2fIWIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:owrDWSWdHWjQEoH3SUmE> NWrQfmxFOjR5MUC2N|E>
HeLa MkL1SpVv[3Srb36gRZN{[Xl? NFTsUY0ydU1? NFL6flExNjWq NIPCXGFi[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= NW\admI1OjR5MEe0O|Q>
ACP02 M{D5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnnSldFOjVyL{O1NE82ODCwTR?= MW[yOIg> M1PQcoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NWjKboJHOjR4Nki1OFc>
ACP03 M3jvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH0S|d4OjVyL{O1NE82ODCwTR?= M1roNlI1cA>? NEXJZpdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P M3P4N|I1PjZ6NUS3
U87 GBM M{f1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknCNVAxNzNyMD:1NFAhdk1? M33JUFczKGh? MWCxNFAmKGW2aHHuc4w> NH;4NnNz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> NFvyNI8zPDR4NEi0NS=>
U87 GBM NHfobFRHfW6ldHnvckBCe3OjeR?= NGjqPXAyODBxNUCwJG5u M3XCTVQ5KGh? MXmxNFAmKGW2aHHuc4w> MX3JcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> M3frc|I1PDZ2OESx
RPE NHvKN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMlIwOC52L{CuPE8yKM7:TR?= MVGyOE81QC95MjDo MY\EUXNQ M3\QNolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 NH7JWJQzPDR3Nk[wNi=>
HT29  NX;Nb5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TwUlE5OCCwTR?= NET5ToE4OiCq NVTlepBRUUN3MDDv[kAyQDBibl2= NYqzTnc6OjR|NkiyOlU>
hMSCs Ml6xSpVv[3Srb36gRZN{[Xl? MVm2MlI2KG6P MUmyOEBp MWHEUXNQ M2GwRpN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= NYLEcollOjR|MUKzOVY>
Huh7  M2qwW2Z2dmO2aX;uJGF{e2G7 MX[wMlEwOC53L{GuNEDPxE1? NYDYeJlbOjSq MWTzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? M1;u[VI1OjZ7Nkey
SKOV3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKwMlA2NTJizszN NFSwbnoyOC9{ND:0PEBp M{XZWmROW09? M{DIVI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NIj0SVkzPDJ{M{iwNS=>
A2780 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zQOFAvODVvMjFOwG0> NV;LVmdZOTBxMkSvOFghcA>? NGSwXmFFVVOR NHL1Vm1u\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NEnTZlkzPDJ{M{iwNS=>
SRA01/04  M2\LdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGwMlIh|ryP NUjY[2xmPDhiaB?= NVK4cmNYTE2VTx?= NUPGSFh6e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MlT3NlQyPTd6N{i=
HLEB3 NXnTfVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXPNE4zKM7:TR?= NFL4OXQ1QCCq MmLnSG1UVw>? NUTL[Wdze3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? M3vGfVI1OTV5OEe4
SRA01/04  M36ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnUNE41NzBwODFOwG0> M2\KfVQ5KGh? M2LGcmROW09? NYjXcohUcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MV2yOFE2Pzh5OB?=
HLEB3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X1NlAvPC9yLkig{txO MkmxOFghcA>? MmHYSG1UVw>? NYX2cZlncW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXGyOFE2Pzh5OB?=
HCT116 NHzod3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr4eXlIOC5{IN88US=> M3jvWFEzKGh? MXrlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= NHHLSIUzPDF{MkKzNS=>
CA46 M1vOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\nN{83NzF{L{K0M|Q5KG6P NHrBfZc1QCCq NV76eHZScW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= MUiyOFA3PDl3MR?=
PMNs NUX0U49pTnWwY4Tpc44hSXO|YYm= M1v6OlMxKG6P NHflOVA1QCCq M{KzNYlvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> NH74bpAzOzl6OE[xOy=>
H1299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXmU3kyyqEQvF5CpC=> NX;JU2RmOjRxNEivO|IhcA>? M2n4e4V1cGGwb3y= M3G0PYlv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? MYeyN|kyPjZyOR?=
A549 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGwMlI2NzBwNT:xJO69VQ>? MmH2NlQwPDhxN{KgbC=> NF\l[YlmfGijbn;s M4ruSIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NFLuemszOzh4N{m5NS=>
H1299 NF7SR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe2NE4zPS9yLkWvNUDPxE1? MnX6NlQwPDhxN{KgbC=> MUXleIhidm:u NH30fVlqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M1zVVFI{QDZ5OUmx
A549 M2O0fmFxd3C2b4Ppd{BCe3OjeR?= MUiwMlUwOSEQvF2= MofVOFghcA>? M2HVboV1cGGwb3y= Mm[0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1z4WlI{QDZ5OUmx
H1299 NYPQSoF3SXCxcITvd4l{KEG|c3H5 MkjINE42NzFizszN NFPYXI01QCCq Mlfp[ZRp[W6xbB?= NHXa[2VqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4izTlI{QDZ5OUmx
SUM149PT NFjBfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW1UVhDOi95LkWvNVAh|ryP NEjrUFk1QCCq NFvRO3dFVVOR NULuTYNbcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= M4Xsc|I{Pzl{NkO4
SUM190PT M1HkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjoOVAwOTByL{K1NEBvVQ>? MXm0PEBp MW\EUXNQ NFj3bYVqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? NXntVmFZOjN5OUK2N|g>
HCT1 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ez[lAvOi9zLkCvOU4xKM7:TR?= NIX0NoQyOi9{ND:zOk81QCCq Ml:5bY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M3fMXVI{PzdyMECw
Lovo NViyZYF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMlIwOS5yL{WuNEDPxE1? M2Kxc|EzNzJ2L{O2M|Q5KGh? MYTpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M1O0WlI{PzdyMECw
AGS M{nke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4mzPVAvODF3LUGg{txO MWC3NkBp M1:4PIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M2CyblI{PzR3MEK0
Huh7 NFHlbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDrNUDPxE1? MWeyOEBp NXPlRVJLTE2VTx?= Mni3doVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NGHCTZAzOzZ2M{mzNy=>
ECC1 MW\GeY5kfGmxbjDBd5NigQ>? MWm1NFAhdk1? M1HacFUh\A>? NIjpTpVFVVOR NGDnOFdqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M4LIeVI{PTNyN{[5
HEC1A NX\3SZNVTnWwY4Tpc44hSXO|YYm= NWfRdZpZPTByIH7N MV:1JIQ> MUjEUXNQ MnnabY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NWjG[|RYOjN3M{C3Olk>
EN1 NFHVeGFHfW6ldHnvckBCe3OjeR?= NIjuOpU2ODBibl2= NY\XUmZFPSCm NWTCW2tETE2VTx?= MoHTbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? Mm\vNlM2OzB5Nkm=
MFE296 MnX4SpVv[3Srb36gRZN{[Xl? MXm1NFAhdk1? NXrp[olLPSCm NYHzfGdCTE2VTx?= MX\pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MYeyN|U{ODd4OR?=
HASMCs MmrpSpVv[3Srb36gRZN{[Xl? MmnsNE02ODBibl2= MmPkOkBl NH;3ToZld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? NF35PIEzOzVzOES2Oy=>
U373 MnnoSpVv[3Srb36gRZN{[Xl? Mk\RNE4zPS9yLkWvNUDPxE1? M3\pRVI1KGh? MXrpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MoX0NlM1PzRzN{G=
ARN8  M4L3T2Z2dmO2aX;uJGF{e2G7 NIfxT5cxNjB3LUKg{txO NXu4eXlKOjRiaB?= NEHtOYtz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? Mo\CNlM1PzB3NEC=
MCF7 M4rN[mZ2dmO2aX;uJGF{e2G7 NYP4WHZSOC5yNT2yJO69VQ>? NXL5SWVVOjRiaB?= Mlz6doVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> M3ewelI{PDdyNUSw
H1299  NVXTW2o1TnWwY4Tpc44hSXO|YYm= NGPXbFAxNjN|4pETNeKhyrWP NUi4dm1kOjRxNEigbC=> MmDKSG1UVw>? MnTUbY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= MlPSNlM1PjF7N{W=
H1299 NXKzSFhXTnWwY4Tpc44hSXO|YYm= MVKwMlUh|ryP NX:yTJY2PDhiaB?= M2jW[mROW09? MmXwbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> NYDHVFBDOjN2NkG5O|U>
H1299 NIjScGtHfW6ldHnvckBCe3OjeR?= MV2wMlUh|ryP NGCyO5k1QCCq MnT2SG1UVw>? MX7pcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MnPUNlM1PjF7N{W=
MG-63  Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DwblAvOyEQvF2= Mn73NVIuQTZiaB?= M3fZTWROW09? NITMcFdqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu Mly1NlM1PTF6MUe=
LM8 NU\NVIxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSzTVFHOC5|IN88US=> NXrO[2JFOTJvOU[gbC=> MXzEUXNQ M12zTIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= NVvXSpk2OjN2NUG4NVc>
K562 NEDaOZRHfW6ldHnvckBCe3OjeR?= NX24dml[OC53IN88US=> NUPvZmc5OjRiaB?= Mn3p[ZRp[W6xbB?= MmCy[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> M37ySFI{PDNyOUW3
HEL M4rVT2Z2dmO2aX;uJGF{e2G7 NXPXfWVTOC53IN88US=> NFH2PFgzPCCq NVTzXINb\XSqYX7vcC=> M1TKToRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv Moj2NlM1OzB7NUe=
HL60 M36zSmFxd3C2b4Ppd{BCe3OjeR?= M{LneVEh|ryP NFe2O5gzPCCq M1;SZolv\HWlZYRCpINmdGxiZHXheIg> MVmyN|QxODVzOR?=
KG1 MVLBdI9xfG:|aYOgRZN{[Xl? MWGxJO69VQ>? M2SyU|I1KGh? MUnpcoR2[2W|wrDj[YxtKGSnYYTo M{S2TlI{PDByNUG5
Kazumi NFzQbohCeG:ydH;zbZMhSXO|YYm= MWCxJO69VQ>? M{PIU|I1KGh? MofpbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MX:yN|QxODVzOR?=
K562 M2\tbmFxd3C2b4Ppd{BCe3OjeR?= NF3BOZIyKM7:TR?= NH3i[4ozPCCq NXfENHhncW6mdXPld:Kh[2WubDDk[YF1cA>? M{f0WVI{PDByNUG5
THP1 MnPwRZBweHSxc3nzJGF{e2G7 NUTuNWRZOSEQvF2= NGnPdJIzPCCq NULLOYNFcW6mdXPld:Kh[2WubDDk[YF1cA>? M3fPOVI{PDByNUG5
SH-SY5Y NXr6Vm1HTnWwY4Tpc44hSXO|YYm= MXqyOVAhdk1? NFrEfWsyPiCq NF\YfFBkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 NYjQ[WdoOjN|Mk[0NlI>
HEK293 MUPGeY5kfGmxbjDBd5NigQ>? Ml3YNUDDvU4EoB?= NGW5fnYyQCCqwrC= MVnpcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{ NHrEe4MzOzJ6NEi0PC=>
HTK Mni0SpVv[3Srb36gRZN{[Xl? NX3uWmdNPDByIH7N MYK3NkBp NUHIT2ZrcW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? MXKyN|I5PDByMh?=
HTK NVTpTpZITnWwY4Tpc44hSXO|YYm= NIrNcVQyODBvOECwcm0> Mo\IO|IhcA>? M4PBSYJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w NYPkO5FrOjN{OESwNFI>
Caco-2  MkHCSpVv[3Srb36gRZN{[Xl? MnntNUDDvU4EoB?= NITzU3QzPCCq MWnk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? MWeyN|E6PTB5MB?=
HeLa MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNFAhdk1? NX3pU29GOjRiaB?= MUjEUXNQ M4fid2lEPTBib3[gNVAxdk1? NGThWXkzOzF4NUe0PC=>
HeLa NV;ycVRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLIcohXPDBibl2= M1v4dlQ5KGh? MYTEUXNQ MYLJR|UxKG:oIESwcm0> NV3MTJByOjNzNkW3OFg>
HeLa NWPVeo5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmyNEBvVQ>? MmfBO|IhcA>? M2CwcGROW09? NVnOPJJvUUN3MDDv[kAzOG6P MVGyN|E3PTd2OB?=
HeLa MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNE8{OC93MDDuUS=> NHPGUYk4OiCq NI\LclVFVVOR MWHpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= NHXpOWwzOzF4NUe0PC=>
MDA-MB-231 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjUYczPS12MECgcm0> MoHoOFghcA>? NX7zR4hVUUN3MDDv[kAzPjNwMn7NxsA> M2jVdFI{ODV3MUm4
MCF-7  NV\L[XRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXmNlUuPDByIH7N M2Lwe|Q5KGh? M{LSXWlEPTBib3[gNlIxNjSwTR?= MkfjNlMxPTVzOUi=
ECC-1  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq3RmoyODBibl2= NWPGTZEzOjRiaB?= Moj5[ZRp[W6xbB?= MljwbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn M3G0e|I{ODJ6OECz
HEC-1A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNFAhdk1? MnPHNlQhcA>? NF;ZNYNmfGijbn;s M4[zUYlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= M{Xv[lI{ODJ6OECz
NHAC-kn NIfVeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNE8yODBxNUCwJI5O NETtOJYyOiCq MlHqSG1UVw>? NGHxS2JKSzVyIH;mJFUxOG6P NWP3[ohlOjNyMUe4O|E>
A549 NEHZeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjafZExOjVyIH7N NUDOSWU2Pi15MjDo NHjkVndFVVOR MlfIZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> NIDJfHczOjl7NEe4NC=>
MG-63 M3nNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCzNFAhdk1? M4TMU|EzKGh? M2PBOGROW09? MkL6bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? Ml3NNlI4QTl|M{i=
MG-63 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHKOog{ODBibl2= NXX1dmhoOjRiaB?= NIPndFRFVVOR MojibY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>? NFG5bJczOjd7OUOzPC=>
MG-63 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\pN|AxKG6P NFH0R4s1QCCq Mkm5SG1UVw>? Mn2ybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? Mn3ONlI4QTl|M{i=
HL60  NFHtOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7HTo44OTVyLUO1NEBvVQ>? NYXKZWt3OjRiaB?= NWfYWoM2cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? M2S4VVIzPzV|N{O5
U937 NXfnO4lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\tNVUxNTN3MDDuUS=> NFXidVYzPCCq MkHTbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MWCyNlc2Ozd|OR?=
SCC-6 NGfjUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\3NlAxNTN{MECgcm0> MXSxNk8zPC92ODDo M1P0NGROW09? MVTpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NFfIW5EzOjV3MkOyNS=>
U87  NH\6XJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\0RoRqOTByLUOwNEBv\w>? M4K0TlI1KGh? MmnwbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? MoPaNlIzPzB6NEm=
K562 M4D5eGZ2dmO2aX;uJGF{e2G7 MmXGNUDPxE1? NXzqN4ZNOTJiaB?= NWXLdJVsTE2VTx?= NYHmZm5b\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> M2K5dVIzOTd7MUm4
Reh NXLjV5hjTnWwY4Tpc44hSXO|YYm= M4H6WlAvOy9zIN88US=> MWCxNkBp Mm\kSG1UVw>? NFmzXFZmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NF;6SVYzOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data

体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型,持续处理4周,具有有效的抗癌活性,即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症(SMA)模型鼠,导致乙酰化的 H3 和 H4组蛋白水平提高,也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠,促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时,或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火,然后使用600 μL 乙酸乙酯进行抽提,通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据,绘制合适的剂量反应曲线,而测定IC50。
细胞实验:[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3

CAS号 58880-19-6
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID